ZA200505419B - Substituted hexahydropyraxino(1,2,-A)pyrmidin,-4,7-dionderivatives, method for the production and use thereof as medicaments - Google Patents

Description

Description

Substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives, method for the production and use thereof as medicaments

The invention relates to substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives and to the physiologically tolerated salts and physiologically functional derivatives thereof.

The invention was based on the object of providing compounds which bring about a weight reduction in mammals and which are suitable for the prevention and treatment of obesity.

The invention therefore relates to compounds of the formula I,

R4

R3 2 R5 0=5=0

N _R1 che ON

R6 N

Ee

R2 0 (CH m

A

I in which the meanings are

A 3-12 membered mono-, bi- or spirobicyclic ring which may comprise one or more heteroatoms from the group of N, O and S and the 3-12 membered ring may have further substituents such as F, Cl, Br, NO,, CFs, OCF3;, CN, (C,-Ce)-akkyl, aryl, CON(R11)(R12), N(R13)(R14), OH, O-(C,-C¢)-alkyl,

S-(C;-Ce)-alkyl, N(R15)CO(C,-Cs)-alkyl or COO-(C;-Cs)-alkyl;

R11, R12, R13, R14, R15 independently of one another H, (C,-Cs)-alkyl, heterocycle; al n 0, 1; m 0,1,2,3,4,5,6;

RI R8, (C,-Cs)-alkylene-R8, (C,-Cs)-alkenylene-R9, (SO;)-R8, (S0,)-(C;-Ce)- alkylene-R8, (S0O,)-(C,-C¢)-alkenylene-R9, (C=0)-R8, (C=0)-(C;-Cq)- alkylene-R8, (C=O)NH-RS8, (C=0)-(C,-C¢)-alkenylene-R9, (C=0)-NH-(C;-

Ce)-alkylene-R8, (C=0)-NH-(C,-Ce)-alkenylene-R9, COO-R8, COO-(C;-

Ce)-alkylene-R8, COO-(C,-C¢)-alkenylene-R9, alkynylene-R9, (C,-Cs- alkyl)-heterocycle, where the alkylene groups may be substituted by F;

R8, RY independently of one another H, F, C1, Br, I, OH, CF;3, aryl, heterocycle, (C;-Cs)-cycloalkyl, where the rings or ring systems may be substituted up to 3 times by F, Cl, Br, I, OH, CF;, NO», CN, OCF;, O-(C;-C¢)-alkyl, (C,-Cs)- alkyl, NH,, CON(R11)(R12), N(R13)(R14), SO,-CH3, COOH, COO-(C;-

Ce)-alkyl, CONH,;

R2 H, F, Cl, Br, I, OH, CF3;, CN, OCF;, O-(C,-C¢)-alkyl, O-(C;-C4)-alkoxy-(C;-

Cs)-alkyl, S-(C,-Cg)-alkyl, (C,-Cs)-alkyl, (C.-Ce)-alkenyl, (C3.Cg)- cycloalkyl, O-(C;-Cg)-cycloalkyl, (C;-Cs)-cycloalkenyl, O-(C;-Csg)- cycloalkenyl, (C,-Ce)-alkynyl, aryl, O-aryl, (C,-Cg)-alkylene-aryl, O-(C,-

Cg)-alkylene-aryl, S-aryl, CON(R11)(R12), N(R13)}(R14), (C;-Cs)- alkyl-N(R13)(R14), COOH, COO-(C,-C¢)-alkyl, COO-(C,-C¢)-alkenyl, CO-

N((C,-Ce)-alkyl), heterocycle, where the heterocycle may not be bonded via a nitrogen atom;

R3,R4,R5 independently of one another H, F, Cl, Br, I, OH, CF3, NO, CN, OCF;, O- (C,-Ce)-alkyl, O-(C;-C4)-alkoxy-(C,-Cq)-alkyl, S-(Cy-Ce)-alkyl, (C,-Cq)- alkyl, (C,-Ce)-alkenyl, (C3-Csg)-cycloalkyl, O-(C;-Cs)-cycloalkyl, (C3-Cg)- cycloalkenyl, O-(C;-Cs)-cycloalkenyl, (C,-Cs)-alkynyl, aryl, O-aryl (C,-Cq)- -

alkylene-aryl, O-(C,-Cg)-alkylene-aryl, S-aryl, N((C,;-C¢)-alkyl),, SO,-CHs,

COOH, COO-(C,-Cg)-alkyl, CO-N((C,-Cg)-alkyl);;

R6 H, F, Cl, Br, I, OH, CF3, NO, CN, OCEF;, O-(C,-Ce)-alkyl, O-(C,-C4)- alkoxy-(C,-Cs)-alkyl, S-(C,-Cg)-alkyl, (C,-Cs)-alkyl, (C,-Cg)-alkenyl, (Cs-

Cg)-cycloalkyl, O-(C;-Cs)-cycloalkyl, (C3-Cg)-cycloalkenyl, O-(C;-Cs)- cycloalkenyl, (C,-C¢)-alkynyl, (Co-Cs)-alkylene-aryl, O-(Cy-Cs)-alkylene- aryl, S-aryl, N((C,-Cs)-alkyl);, SO,-CHj;, COOH, COO-(C;-Ce)-alkyl, CO-

N((C,-Cg)-alkyl),; and the physiologically tolerated salts thereof.

Preference is given to compounds of the formula I in which the meanings are

A 3-12 membered mono-, bi- or spirobicyclic ring which may comprise one or more heteroatoms from the group of N, O and S and the 3-12 membered ring may have further substituents such as F, Cl, Br, NO,, CF3;, OCF;, CN, (C,-Ce)-alkyl, aryl, CON(R11)(R12), N(R13)(R14), OH, O-(C,-Cg)-alkyl,

S-(C;-Ce)-alkyl, N(R15)CO(C,-C¢)-alkyl or COO-(C;-Ce)-alkyl;

R11, R12, R13, R14, R15 independently of one another H, (C;-C¢)-alkyl, heterocycle; m 1; n 0,1;

R1 RS, (C;-Cg)-alkylene-R8, (C,-Ce)-alkenylene-R9, (SO,)-R8, (S0,)-(C;-Cg)- alkylene-R8, (§0,)-(C,-Ce)-alkenylene-R9, (C=0)-R8, (C=0)-(C,-Cs)- alkylene-R8, (C=O)NH-R8, (C=0)-(C,-Cs)-alkenylene-R9, (C=0)-NH-(C,-

Ce)-alkylene-R8, (C=0)-NH-(C,-C¢)-alkenylene-R9, COO-R8, COO-(C;-

Ce)-alkylene-R8, COO-(C,-Ce)-alkenylene-R9, alkynylene-R9, (C,-Cs- alkyl)-heterocycle; ) 1d i " ®

R8, R9 independently of one another H, F, C1, Br, I, OH, CFs, aryl, heterocycle, (C5-Cg)-cycloalkyl, where the rings or ring systems may be substituted up to 3 times by F, Cl, Br, I, OH, CF;, NO,, CN, OCF, O-(C;-C¢)-alkyl, (C,-Ce)- alkyl, NH;, CON(R11)(R12), N(R13)(R14), SO.-CH3, COOH, COO-(C;-

Ce)-alkyl, CONH;;

R2 H, F, Cl, Br, I, OH, CF3, CN, OCF;, O-(C;-C¢)-alkyl, O-(C;-C4)-alkoxy-(C;-

Ca)-alkyl, S-(C,-Cq)-alkyl, (C,-Ce)-alkyl, (C,-Ce)-alkenyl, (C;.Cs)- cycloalkyl, O-(C;-Cs)-cycloalkyl, (C;-Cg)-cycloalkenyl, O-(C3-Cg)- cycloalkenyl, (C;-Cg)-alkynyl, aryl, O-aryl, (C,-Cs)-alkylene-aryl, O-(C;-

Cs)-alkylene-aryl, S-aryl, CON(R11)(R12), N(R13)(R14), (C,-C¢)- alkyl-N(R13)(R14), COOH, COO-(C,;-Cs)-alkyl, COO-(C,-C¢)-alkenyl, CO-

N((C,-Cq)-alkyl),, heterocycle, where the heterocycle may not be bonded via a nitrogen atom,

R3,R4, R5 independently of one another H, F, Cl, Br, I, OH, CF;, NO,, CN, OCF;3, O- (C1-Ce)-alkyl, O-(C,-Cy)-alkoxy-(C;-Ca)-alkyl, S-(C,-Ce)-alkyl, (C,-Cs)- alkyl, (C;-Ce)-alkenyl, (C;3-Cs)-cycloalkyl, O-(C;-Cs)-cycloalkyl, (C3-Cg)- cycloalkenyl, O-(Cs-Cg)-cycloalkenyl, (C,-Cs)-alkynyl, aryl, O-aryl (Co-Csg)- alkylene-aryl, O-(Co-Cs)-alkylene-aryl, S-aryl, N((C,-C¢)-alkyl),, SO,-CH;,

COOH, COO-(C,-Ce)-alkyl, CO-N((C,-C¢)-alkyl);

R6 H, F, Cl, Br, I, OH, CF3, NO,, CN, OCF3, O-(C,-Ce)-alkyl, O-(C,-C,)- alkoxy-(C;-Ca)-alkyl, S-(C;-Cq)-alkyl, (C,-Cs)-alkyl, (C>-Cs)-alkenyl, (C;-

Cs)-cycloalkyl, O-(C3-Cg)-cycloalkyl, (C3-Cg)-cycloalkenyl, O-(C3-Cs)- cycloalkenyl, (C;-Ce)-alkynyl, aryl, O-aryl, (C,-Cs)-alkylene-aryl, O-(C,-

Cg)-alkylene-aryl, S-aryl, N((C,-Cg)-alkyl),, SO,-CH3;, COOH, COO-(C;-

Ce)-alkyl, CO-N((C,-C¢)-alkyl),; and the physiologically tolerated salts thereof. ) ol

Particular preference is given to compounds of the formula I in which the meanings are

A aryl, where the aryl ring may be substituted by F, Cl, Br, NO,, CFs, OCF3,

CN, (C,-Cg)-alkyl, aryl, CON(R11)(R12), N(R13)(R14), OH, O-(C,-Cg)- alkyl, S-(C,-Cg)-alkyl, N(R15)CO(C,-C¢)-alkyl or COO-(C,-Cs)-alkyl;

R11, R12, R13, R14, R15 independently of one another H, (C-Ce)-alkyl; m 1;

R1 (C1-Ce)-alkylene-R8, (C,-C¢)-alkenylene-R9;

R8, R9 independently of one another H, F, Cl, Br, I, OH, CF;, aryl, heterocycle, (Cs-

Csg)-cycloalkyl, where the rings or ring systems may be substituted up to 3 times by F, Cl, Br, I, OH, CFs, NO,, CN, OCF3, O-(C,-C¢)-alkyl, (C,-Cg)- alkyl, NH,, CON(R11)(R12), N(R13)(R14), SO,-CH3, COOH, COO-(C;-

Ce)-alkyl, CONH,;

R2 H, F, Cl, Br, I, OH, CF;, CN, OCF;, O-(C,-C¢)-alkyl, (C;-C¢)-alkyl, COO- (Cy-Co)-alkenyl, N(R13)(R14), (C,-C¢)-alkyl-N(R13)(R14);

R3 H;

R4,R5 independently of one another H, F, Cl, Br, OH, CF;, OCF;, O-(C,-Ce)-alkyl, (C1-Ce)-alkyl,

R6 H; and the physiologically tolerated salts thereof.

SE ul

Very particular preference is given to compounds of the formula I in which the meanings are

A aryl, where the aryl ring may be substituted by F, Cl, Br, NO,, CF;, OCF,

CN, (C,-Ce)-alkyl, aryl, CON(R11)(R12), N(R13)(R14), OH, O-(C,-Cs)- alkyl, S-(C,-Ce)-alkyl, N(R15)CO(C,-C¢)-alkyl or COO-(C,;-Cs)-alkyl;

R11, R12, R13, R14, R15 independently of one another H, (C,-Cg¢)-alkyl; m 1; n 0,1;

R1 (C,-Ce)-alkyl, (C,-Ce)-alkenyl;

R2 H, OH, (C;-C¢)-alkyl, COO-(C,-Cs)-alkenyl, (C,-C¢)-alkyl-N(R13)(R14);

R3 H;

R4 F, Cl, Br, OH, CF;, OCF3, O-(C;-Ce)-alkyl, (C,-Cs)-alkyl;

RS H, F, Cl, Br, OH, CF;, OCF; 0-(C,-Ce)-alkyl, (C,-Co)-alkyl,

R6 H; and the physiologically tolerated salts thereof.

If radicals or substituents can occur more than once in the compounds of the formula I, such as, for example, CON(R11)(R12), they may all independently of one another have the stated meanings and be identical or different.

The invention relates to compounds of the formula I in the form of their racemates, enantiomer-enriched mixtures and pure enantiomers, and to their diastereomers and mixtures thereof. ) ud

: . _

The alkyl, alkenyl and alkynyl radicals in the substituents A, R1, R2, R3, R4, R5, R6, RS,

R9, R10, R11, R12, R13, R14, R15 may be either straight-chain, branched or optionally halogenated. The alkyl radicals in the substituents A, R1, R2, R3, R4, RS, R6, R§, R9,

RI10,R11, R12, R13, R14, R15 may also by cyclic.

The term “aryl” means a phenyl or naphthyl group.

Heterocycle or heterocyclic radical means ring systems which, apart from carbon, also comprise heteroatoms such as, for example, nitrogen, oxygen or sulfur. Ring systems in which the heterocycle or the heterocyclic radical is fused to benzene nuclei are also included in this definition.

Suitable “heterocyclic rings” and “heterocyclic radicals” are acridinyl, azocinyl, benzimidazolyl, benzofuryl, benzothienyl, benzothiophenyl, benzoxazolyl, benzothiazolyl, benzotriazolyl, benzotetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazalinyl, carbazolyl, 4aH-carbazolyl, carbolinyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 2H,6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b]tetrahydrofuran, furyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 1H-indazolyl, indolinyl, indolizinyl, indolyl, 3H-indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinoliny! (benzimidazolyl), isothiazolyl, isoxazolyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5- oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxazolidinyl, pyrimidinyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazoles, pyridoimidazoles, pyridothiazoles, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, 6H-1,2,5- thiadazinyl, thiazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4- thiadiazolyl, thienyl, triazolyl, tetrazolyl and xanthenyl. ) A i . ®

Pyridyl stands both for 2-, 3- and 4-pyridyl. Thienyl stands both for 2- and 3-thienyl. Furyl stands both for 2- and 3-furyl.

Also included are the corresponding N-oxides of these compounds, that is to say, for example, 1-oxy-2-, 3- or 4-pyridyl.

Also included are derivatives of these heterocycles which are benzo-fused one or more times.

The heterocyclic rings or heterocyclic radicals may be substituted one or more times by suitable groups such as, for example: F, Cl, Br, I, CF3, NO,, N3, CN, COOH,

COO(C,-Ce)alkyl, CONH,, CONH(C,-Cg)alkyl, CON[(C;-Cs)alkyl],. (C,-Cs)-alkyl, (C,-Ce)-alkenyl, (C,-Cg)-alkynyl, O-(C;-C¢)-alkyl, where one, more than one or all hydrogen(s) in the alkyl radicals may be replaced by fluorine; PO;H,, SO;3H, SO,;-NH,, SO,NH(C,-Ce)-alkyl, SO,N[(C,-Ce)-alkyl], , S-(C;-C¢)-alkyl,

S-(CHz)n-phenyl, SO-(C,-Cg)-alkyl, SO-(CH,),-phenyl, SO,-(C,-Cs)-alkyl, SO,-(CH;),- phenyl, where n can be 0-6, and the phenyl radical may be substituted up to twice by F, Cl,

Br, OH, CF3, NO,, CN, OCF3, O-(C;-Cg)-alkyl, (C,;-Ce)-alkyl, NH>;

C(NH)(NH;), NH;, NH-(C,-Cs)-alkyl, N((C,-C¢)-alkyl),, NH(C,-C-)-acyl, phenyl, O-(CH2)n-phenyl, where n can be 0—6, where the phenyl ring may be substituted one to 3 times by F, Cl, Br, I, OH, CF3, NO,, CN, OCF3, O-(C,-C¢)-alkyl, (C,-C¢)-alkyl, NH,,

NH(C,-C¢)-alkyl, N((C,-Cs)-alkyl),, SO,-CH3;, COOH, COO-(C,-Cg¢)-alkyl, CONHj.

Pharmaceutically acceptable salts are particularly suitable for medical applications because their solubility in water is higher than the initial or basic compounds. These salts must have a pharmaceutically acceptable anion or cation. Suitable pharmaceutically acceptable acid addition salts of the compounds according to the invention are salts of inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric, metaphosphoric, nitric, sulfonic and sulfuric acids, and organic acids such as, for example, acetic acid, benzenesulfonic, benzoic, citric, ethanesulfonic, fumaric, gluconic, glycolic, isethionic, lactic, lactobionic, maleic, malic, methanesulfonic, succinic, p-toluenesulfonic, tartaric and trifluoroacetic acids. The chloride salt is particularly preferably used for medical purposes. Suitable pharmaceutically acceptable basic salts are ammonium salts, alkali metal salts (such as ) | d

: . ® sodium and potassium salts) and alkaline earth metal salts (such as magnesium and calcium salts).

Salts with a pharmaceutically unacceptable anion likewise fall within the scope of the invention as useful intermediates for preparing or purifying pharmaceutically acceptable salts and/or for use in nontherapeutic, for example in vitro, applications.

The term “physiologically functional derivative” used herein refers to any physiologically tolerated derivative of a compound according to the invention of the formula I, for example an ester, which is able on administration to a mammal such as, for example, a human to form (directly or indirectly) a compound of the formula I or an active metabolite thereof.

The physiologically functional derivatives also include prodrugs of the compounds according to the invention. Such prodrugs can be metabolized in vivo to a compound according to the invention. These prodrugs may themselves be active or not.

The compounds according to the invention may also exist in various polymorphous forms, for example as amorphous and crystalline polymorphous forms. All polymorphous forms of the compounds according to the invention lie within the scope of the invention and are a further aspect of the invention.

All references hereinafter to “compound(s) of formula (I)” refer to compound(s) of the formula (I) as described above, and the salts, solvates and physiologically functional derivatives thereof as described herein.

The amount of a compound of formula (I) which is necessary to achieve the desired biological effect depends on a number of factors, for example the specific compound chosen, the intended use, the mode of administration and the clinical condition of the patient. In general, the daily dose is in the range from 0.3 mg to 100 mg (typically from 3 mg to 50 mg) per day and per kilogram of body weight, for example 3-10 mg/kg/day. An intravenous dose may be, for example, in the range from 0.3 mg to 1.0 mg/kg, which can most suitably be administered as infusion of from 10 ng to 100 ng per kilogram and per minute. Suitable infusion solutions for these purposes may contain, for example, from ) v

0.1 ng to 10 mg, typically from 1 ng to 10 mg, per milliliter. Single doses may contain, for example, from 1 mg to 10 g of the active ingredient. It is thus possible for ampoules for injections to contain, for example, from 1 mg to 100 mg, and single-dose formulations which can be administered orally, such as, for example, tablets or capsules, to contain, for example, from 1.0 to 1000 mg, typically from 10 to 600 mg. In the case of pharmaceutically acceptable salts, the aforementioned weight data are based on the weight of the free compound on which the salt is based. For the prophylaxis or therapy of the abovementioned conditions, the compounds of formula (I) can be used as the compound itself, but they are preferably in the form of a pharmaceutical composition with an acceptable carrier. The carrier must, of course, be acceptable in the sense that it is compatible with the other ingredients of the composition and is not hazardous for the patient's health. The carrier may be a solid or a liquid or both and is preferably formulated with the compound as single dose, for example as tablet which may contain from 0.05% to 95% by weight of the active ingredient. Further pharmaceutically active substances may likewise be present, including other compounds of formula (I). The pharmaceutical compositions according to the invention can be produced by one of the known pharmaceutical methods which essentially consist of mixing the ingredients with pharmacologically acceptable carriers and/or excipients.

Pharmaceutical compositions according to the invention are those suitable for oral, rectal, topical, peroral (for example sublingual) and parenteral (for example subcutaneous, intramuscular, intradermal or intravenous) administration, although the most suitable mode of administration in each individual case depends on the nature and severity of the condition to be treated and on the nature of the compound of formula (I) used in each case.

Coated formulations and coated slow-release formulations also lie within the scope of the invention. Formulations resistant to acid and gastric fluid are preferred. Suitable coatings resistant to gastric fluid comprise cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxypropylmethylcellulose phthalate and anionic polymers of methacrylic acid and methyl methacrylate.

Suitable pharmaceutical compounds for oral administration may be in the form of separate units such as, for example, capsules, cachets, suckable tablets or tablets, each of which contain a defined amount of the compound of formula (I); as powders or granules; as solution or suspension in an aqueous or nonaqueous liquid; or as an oil-in-water or water- ) rr

® in-oil emulsion. These compositions may, as already mentioned, be prepared by any suitable pharmaceutical method which includes a step in which the active ingredient and the carrier (which may consist of one or more additional ingredients) are brought into contact. In general, the compositions are produced by uniform and homogeneous mixing of the active ingredient with a liquid and/or finely divided solid carrier, after which the product 1s shaped if necessary. Thus, for example, a tablet can be produced by compressing or molding a powder or granules of the compound, where appropriate with one or more additional ingredients. Compressed tablets can be produced by tableting the compound in free-flowing form, such as, for example, a powder or granules, where appropriate mixed with a binder, lubricant, inert diluent and/or a (plurality of) surface-active/dispersing agent(s) in a suitable machine. Molded tablets can be produced by molding the compound which is in powder form and is moistened with an inert liquid diluent in a suitable machine.

Pharmaceutical compositions suitable for peroral (sublingual) administration comprise suckable tablets which contain a compound of formula (I) with a flavoring, normally sucrose and gum arabic or tragacanth, and pastilles which comprise the compound in an inert base such as gelatin and glycerol or sucrose and gum arabic.

Suitable pharmaceutical compositions for parenteral administration comprise preferably sterile aqueous preparations of a compound of formula (I), which are preferably isotonic with the blood of the intended recipient. These preparations are preferably administered intravenously, although administration may also take place by subcutaneous, intramuscular or intradermal injection. These preparations can preferably be produced by mixing the compound with water and making the resulting solution sterile and isotonic with blood.

Injectable compositions according to the invention generally contain from 0.1 to 5% by weight of the active compound.

Suitable pharmaceutical compositions for rectal administration are preferably in the form of single-dose suppositories. These can be produced by mixing a compound of formula (I) with one or more conventional solid carriers, for example cocoa butter, and shaping the resulting mixture. ) d

®

Suitable pharmaceutical compositions for topical application to the skin are preferably in the form of an ointment, cream, lotion, paste, spray, aerosol or oil. Carriers which can be used are petrolatum, lanolin, polyethylene glycols, alcohols and combinations of two or more of these substances. The active ingredient is generally present in a concentration of from 0.1 to 15% by weight of the composition, for example from 0.5 to 2%.

Transdermal administration is also possible. Suitable pharmaceutical compositions for transdermal uses can be in the form of single plasters which are suitable for long-term close contact with the patient's epidermis. Such plasters suitably contain the active ingredient in an optionally buffered aqueous solution, dissolved and/or dispersed in an adhesive or dispersed in a polymer. A suitable active ingredient concentration is about 1% to 35%, preferably about 3% to 15%. As a special possibility, the active ingredient can be released as described, for example, in Pharmaceutical Research, 2(6): 318 (1986) by electrotransport or iontophoresis.

The compounds of the formula I are distinguished by beneficial effects on lipid metabolism, and they are particularly suitable for weight reduction and for maintaining a reduced weight after weight reduction has taken placc in mammals and as anorcctic agents.

The compounds are distinguished by their low toxicity and their few side effects.

The compounds can be employed alone or in combination with other weight-reducing or anorectic active ingredients. Further anorectic active ingredients of this type are mentioned, for example, in the Rote Liste, chapter 01 under weight-reducing agents/appetite suppressants, and may also include active ingredients which increase the energy turnover of the organism and thus lead to weight reduction or else those which influence the general metabolism of the organism in such a way that an increased calorie intake does not lead to an enlargement of the fat depots and a normal calorie intake leads to a reduction of the fat depots of the organism. The compounds are suitable for the prophylaxis and, in particular, for the treatment of excessive weight or obesity. The compounds are further suitable for the prophylaxis and, in particular, for the treatment of type II diabetes, of arteriosclerosis and for normalizing lipid metabolism and for the treatment of high blood pressure. The compounds act as melanocortin receptor agonists and are also suitable for the treatment of disturbances of wellbeing and other psychiatric indications such as, for example, depressions, anxiety states, anxiety neuroses, schizophrenia and for the treatment of disorders associated with the circadian rhythm and for the treatment of drug abuse. ) r

®

They are additionally suitable for the treatment of cancer, arthritis, sleep disorders, sleep apnea, female and male sexual disorders, inflammations, acne, pigmentation of the skin, of the metabolic syndrome, disorders of steroid metabolism, cutaneous diseases, psoriasis, mycoses, neurodegenerative diseases and Alzheimer’s disease.

In a further aspect of the invention, the compounds of the formula I can be administered in combination with one or more other pharmacologically active substances which are selected, for example, from antidiabetics, antiobesity agents, active ingredients which lower blood pressure, lipid-lowering agents and active ingredients for the treatment and/or prevention of complications caused by diabetes or associated with diabetes.

Suitable antidiabetics include insulins, amylin, derivatives of GLP-1 and GLP-2 such as, for example, those disclosed in WO 98/08871 of Novo Nordisk A/S, and orally active hypoglycemic active ingredients.

The orally active hypoglycemic active ingredients preferably comprise sulfonylureas, biguanides, meglitinides, oxadiazolidinediones, thiazolidinediones, glucosidase inhibitors, glucagon receptor antagonists, GLP-1 agonists, potassium channel openers such as, for example, those disclosed in WO 97/26265 and WO 99/03861 of Novo Nordisk A/S, insulin sensitizers, activators of insulin receptor kinase, inhibitors of liver enzymes involved in the stimulation of gluconeogenesis and/or glycogenolysis, for example inhibitors of glycogen phosphorylase, modulators of glucose uptake and glucose excretion, compounds which alter lipid metabolism, such as antihyperlipidemic active ingredients and antilipidemic active ingredients, for example HMGCoA reductase inhibitors, inhibitors of cholesterol transport/of cholesterol uptake, inhibitors of bile acid reabsorption or inhibitors of the microsomal triglyceride transfer protein (MTP), compounds which reduce food intake,

PPAR and RXR agonists and active ingredients which act on the ATP-dependent potassium channel of the beta cells.

In one embodiment of the invention, the present compounds are administered in combination with insulin.

In a further embodiment, the present compounds are administered in combination with a sulfonylurea such as, for example, tolbutamide, glibenclamide, glimepiride, glipizide, gliquidone, glisoxepide, glibomuride or gliclazide.

In another embodiment, the present compounds are administered in combination with a biguanide such as, for example, metformin. - y

In yet another embodiment, the present compounds are administered in combination with a meglitinide such as, for example, repaglinide.

In yet a further embodiment, the present compounds are administered in combination with a thiazolidinedione such as, for example, troglitazone, ciglitazone, pioglitazone, rosiglitazone or the compounds disclosed in WO 97/41097 of Dr. Reddy’s Research

Foundation, in particular 5-[[4-[(3,4-dihydro-3-methyl-4-0x0-2-quinazolinylmethoxy]- phenyl]methyl]-2,4-thiazolidinedione.

In a further embodiment, the present compounds are administered in combination with an a-glucosidase inhibitor such as, for example, miglitol or acarbose.

In another embodiment, the present compounds are administered in combination with an active ingredient which acts on the ATP-dependent potassium channel of the beta cells, such as, for example, tolbutamide, glibenclamide, glimepiride, glipizide, gliclazide or repaglinide.

In yet another embodiment, the present compounds are administered in combination with an antihyperlipidemic active ingredient or an antilipidemic active ingredient such as, for example, cholestyramine, colestipol, clofibrate, fenofibrate, gemfibrozil, lovastatin, pravastatin, simvastatin, atorvastatin, cerivastatin, fluvastatin, probucol, ezetimibe or dextrothyroxine.

In a further embodiment, the present compounds are administered in combination with more than one of the aforementioned compounds, e.g. in combination with a sulfonylurea and metformin, a sulfonylurea and acarbose, repaglinide and metformin, insulin and a sulfonylurea, insulin and metformin, insulin and troglitazone, insulin and lovastatin, etc.

The compounds of the invention may additionally be administered in combination with one or more antiobesity agents or appetite-regulating active ingredients.

Active ingredients of these types may be selected from the group consisting of CART agonists, NPY antagonists, MCH antagonists, orexin antagonists, H3 antagonists, TNF agonists, CRF agonists, CRF BP antagonists, urocortin agonists, $3 agonists, MSH (melanocyte-stimulating hormone) agonists, CCK agonists, serotonin-reuptake inhibitors, mixed serotonin- and noradrenaline-reuptake inhibitors, SHT modulators, MAO inhibitors, bombesin agonists, galanin antagonists, growth hormone, growth hormone-relcasing compounds, TRH agonists, modulators of uncoupling proteins 2 or 3, leptin agonists, dopamine agonists (bromocriptine, Doprexin), lipase/amylase inhibitors, antagonists of - y

® cannabinoid receptor 1, modulators of acylation-stimulating protein (ASP), PPAR modulators, RXR modulators, hCNTF agonists or TR-f agonists.

In one embodiment of the invention, the antiobesity agent is leptin or modified leptin.

In another embodiment, the antiobesity agent is dexamphetamine or amphetamine.

In another embodiment, the antiobesity agent is fenfluramine or dexfenfluramine.

In yet another embodiment, the antiobesity agent is sibutramine or the mono- and bisdemethylated active metabolites of sibutramine.

In a further embodiment, the antiobesity agent is orlistat.

In another embodiment, the antiobesity agent is mazindol, diethylpropion or phentermine.

The present compounds may additionally be administered in combination with one or more antihypertensive active ingredients. Examples of antihypertensive active ingredients are beta blockers such as alprenolol, atenol, timolol, pindolol, propranolol and metoprolol,

ACE (angiotensin converting enzyme) inhibitors such as, for example, benazepril, captopril, enalapril, fosinopril, lisinopril, quinapril and rampril, calcium channel blockers such as nifedipine, felodipine, nicardipine, isradipine, nimodipine, diltiazem and verapamil, and alpha blockers such as doxazosin, urapidil, prazosin and terazosin.

Reference may furthermore be made to Remington: The Science and Practice of Pharmacy, 19th edition, Gennaro, editor, Mack Publishing Co., Easton, PA, 1995.

It will be appreciated that every suitable combination of the compounds of the invention with one or more of the aforementioned compounds and optionally one or more other pharmacologically active substances is to be regarded as covered by the scope of protection of the present invention.

The efficacy of the compounds was tested as follows:

Biological test model:

The anorectic effect was tested on female NMRI mice. After withdrawal of food for 24 hours, the test product was administered by gavage. The animals were housed singly with free access to drinking water and were offered condensed milk 30 minutes after administration of the product. The condensed milk consumption was determined every half hour for 7 hours, and the general wellbeing of the animals was observed. The measured milk consumption was compared with the vehicle-treated control animals.

Table 1: Anorectic effect measured as the reduction in the cumulative milk consumption of treated compared with control animals. ) r

Example Oral Number of Number of Reduction in the animals/ animals/ cumulative milk dose cumulative milk | cumulative milk | consumption as % consumption of | consumption of of the control [mg/kg] the treated the control animals animals

N/[ml] N/[ml]

It is evident from the table that the compounds of the formula I show a good anorectic effect and are thus very suitable as antiobesity agent.

The examples and preparation methods detailed below serve to illustrate the invention without, however, restricting it.

General processes

The starting matenals used in the synthesis were purchased from chemicals suppliers such as Aldrich, Acros, Sigma, Fluka, Nova Biochem, Advanced Chemtech, Bachem, Lancaster and other companies.

During the synthesis, the functional groups of the amino acid derivatives used were protected by protective groups to prevent side reactions during the coupling steps.

Examples of suitable protective groups and their use are described in The Peptides, supra, 1981 and in vol. 9, Udenfriend and Meienhofer (editors) 1987 (incorporated herein by reference).

The compounds of the invention were prepared by using general methods of solid-phase synthesis. Such methods are described for example by Steward and Young in Solid Phase

Peptide Synthesis (Freeman & Co., San Francisco 1969) (incorporated herein by reference). i Fr

Unless indicated otherwise, the compounds were synthesized using TentaGel HL12019 resin (Rapp Polymere, Tiibingen). This commercially available polymer contains a bromoacetal linker. This type of coupling can be incorporated into all types of hydroxy-

TentaGel by the process described by Vojkovsky, T. et al, J. Org. Chem. 1998, 63, 3162-3163, and Patek, M., presentation at Combinatorial Chemistry 2000, London, 11.-14.7. 2000 (incorporated herein by reference).

In the first synthesis step (general synthetic scheme, see scheme 1), amine was used in

DMSO to replace bromine in the bromoacetal linkage at a high temperature. Fmoc- protected amino acid was coupled to the secondary amine produced thereby on the polymer. The coupling took place using DIC/HOAt or HATU/DIEA, usually in DMF. The coupling was carried out at room temperature (RT) for 16 hours or at 55°C for 4-5 hours.

Elimination of protection by the Fmoc group took place with 50% piperidine in DMF (5 + 15 minutes). The substitution can be determined by measuring the amount of liberated

Fmoc from the absorbance of the solution at 302 nm after elimination of the protection, the volume of the washing liquid and the weight of the polymer employed in the synthesis in accordance with the description in Krchnak, V. et al., Collect. Czech. Chem. Commun. 53 (1988) 2542 (incorporated herein by reference).

The free amino group on the structure linked to the solid phase was then coupled to Fmoc- beta-alanine (or Fmoc-alpha-amino acid or substituted beta-amino acid). The coupling took place with N,N'-diisopropylcarbodiimide (DIC) in the presence of HOB, usually in DMF.

The completeness of the coupling was monitored by the ninhydrin test.

Elimination of the protection by the Fmoc group was carried out with 50% piperidine in

DMEF for 5 + 15 minutes. The amount of liberated Fmoc was measured from the absorbance of the solution at 302 nm after elimination of the protection, the volume of the washing liquid and the weight of the polymer employed in the synthesis.

The free amino group on the structure linked to the solid phase was then sulfonylated with up to 2 equivalents of a suitable sulfonyl chloride/DIEA in DCM or acetonitrile.

The completeness of the sulfonylation was monitored by the ninhydrin test. ) y

After completion of the assembly of the precursor of the linear compound on the polymer, the solid phase was washed successively with DMF and DCM or THF and dried in vacuo.

The desired compound underwent cyclative cleavage off with formic acid at room temperature for 18-24 hours, at 50°C for 6 hours or by a combination of the two conditions. The polymer was filtered off and washed with DCM or formic acid. The washing liquid was introduced into the formic acid solution. The solution was evaporated.

The residue was dissolved in a mixture of water and acetonitrile and freeze-dried.

The dried compound was purified by HPLC with a suitable gradient of 0.1% TFA in water and acetonitrile (ACN). After collecting the peak containing the desired synthetic product, the solution of the compound was freeze-dried. To confirm that the correct compound had been synthesized, the compound was subjected to a qualitative determination with electrospray mass spectrum (LC/MS) and/or an NMR analysis.

For HPLC analysis, a sample of the compound was analyzed using the Beckman HPLC system (consisting of the solvent feed system 126, the programmable detector module 166 and the autosampler 507¢ and controlled by data station with Gold Nouveau software) with a YMC ODS-AM 4.6 x 250 mm column (8-5 (5 um), YMC, Inc. Wilmington, NC, USA) at 230 nm. At this setting, a flow rate of Iml/min and a gradient of water/0.1% TFA buffer and ACN (HPL quality) was used as eluent. yr

Scheme 1:

Oo pear A

OH

; O

H,NiPr R2

O-t—~ 2M @1— Ro NFmoc

Br N DIC, HOAT N

PR PY R2 7 0 piperidine O—1— A 0 N 0 stati N — R4 _

PY R2 DIC, HOBT 0] Q N R3 N 0]

ST” 0]

O—1— N NTN HCOOH RIN r 1

N H O PEN

R4 oo N NR

Re 0]

R4

The compounds can also be prepared in solution in analogy to the described synthesis on the resin (scheme 2). In place of the functionalized resin, in the first stage 2-bromo-1,1- diethoxyethane is reacted with a primary amine.

Claims (17)

Claims:

1. A compound of the formula I, R4 a R5 0=3=0 _N _~Ri1 a gi N R6 N Oo R20 (Hm A I in which the meanings are A 3-12 membered mono-, bi- or spirobicyclic ring which may comprise one or more heteroatoms from the group of N, O and S and the 3-12 membered ring may have further substituents such as F, Cl, Br, NO,, CF3, OCF3, CN, (C;-C¢)- alkyl, aryl, CON(R11)(R12), N(R13)(R14), OH, O-(C,-C¢)-alkyl, S-(C;-Cg)- alkyl, N(R15)CO(C,-C¢)-alkyl or COO-(C,-C¢)-alkyl; R11, R12, R13, R14, R15 independently of one another H, (C,-Cg¢)-alkyl, heterocycle; n 0, 1; m 0,1,2,3,4,5, 6; R1 RS, (C,-C¢)-alkylene-R8, (C,-Cg¢)-alkenylene-R9, (SO,)-R8 (SO,)-(C,-Cq)- alkylene-R8, (SO,)-(C,-Ce)-alkenylene-R9, (C=0)-R8, (C=0)-(C;-Cs)- alkylene-R8, (C=0)NH-R8, (C=0)-(C;-Cs)-alkenylene-R9, (C=0)-NH-(C,-Cq)-

® alkylene-R8, (C=0)-NH-(C,-C¢)-alkenylene-R9, COO-R8, COO-(C,-C¢)- alkylene-R8, COO-(C,-Ce)-alkenylene-R9, alkynylene-R9, (C,-Cs-alkyl)- heterocycle, where the alkylene groups may be substituted by F;

R8, RY independently of one another H, F, Cl, Br, I, OH, CFj, aryl, heterocycle, (Cs- Cg)-cycloalkyl, where the rings or ring systems may be substituted up to 3 times by F, Cl, Br, I, OH, CF, NO,, CN, OCF3, O-(C;-Cg)-alkyl, (C,-Ce)-alkyl, NH,, CON(R11)(R12), N(R13)(R14), SO,-CH;, COOH, COO-(C;-Cs)-alkyl, CONH;;

R2 H, F, Cl, Br, I, OH, CF3, CN, OCF;3, O-(C,-Cg)-alkyl, O-(C,-Cs4)-alkoxy-(C,- Cy)-alkyl, S-(C,-Ce)-alkyl, (C;-Cs)-alkyl, (C,-Cs)-alkenyl, (C3.Cs)-cycloalkyl, 0O-(Cs-Cg)-cycloalkyl, (C3-Csg)-cycloalkenyl, O-(C;-Cg)-cycloalkenyl, (C,-Ce)- alkynyl, aryl, O-aryl, (C,-Cs)-alkylene-aryl, O-(C,-Cs)-alkylene-aryl, S-aryl, CON(RI11)(R12), N(R13)(R14), (C,-C¢)-alkyl-N(R13)(R14), COOH, COO-(C,- Ce)-alkyl, COO-(C,-Cg)-alkenyl, CO-N((C,-C¢)-alkyl),, heterocycle, where the heterocycle may not be bonded via a nitrogen atom;

R3, R4,R5 independently of one another H, F, Cl, Br, I, OH, CF;, NO,, CN, OCFj3, O-(C;- Ce)-alkyl, O-(C;-Cs)-alkoxy-(C;-Cs)-alkyl, S-(C,-C¢)-alkyl, (C,-C¢)-alkyl, (C,- Cs)-alkenyl, (C;-Cs)-cycloalkyl, O-(C3-Cg)-cycloalkyl, (C;-Cs)-cycloalkenyl, O- (C5-Cs)-cycloalkenyl, (C,-Ce)-alkynyl, aryl, O-aryl (C,-Cs)-alkylene-aryl, O- (C,-Cg)-alkylene-aryl, S-aryl, N((C;-Cs)-alkyl),, SO,-CH;, COOH, COO-(C,;- Ce)-alkyl, CO-N((C,-Cg)-alkyl),;

R6 H, F, Cl, Br, I, OH, CF3, NO,, CN, OCF3, O-(C,-Ce)-alkyl, O-(C,-Cs)-alkoxy- (C1-Cs)-alkyl, S-(C,-Ce)-alkyl, (C;-Ce)-alkyl, (C2-C¢)-alkenyl, (C3-Cys)- cycloalkyl, O-(C;-Cs)-cycloalkyl, (Cs-Cg)-cycloalkenyl, O-(C;-Cs)- cycloalkenyl, (C2-Ce)-alkynyl, (Co-Cg)-alkylene-aryl, O-(Co-Cs)-alkylene-aryl, S-aryl, N((C;-Ce)-alkyl),, SO,-CH3, COOH, COO-(C,;-Cs)-alkyl, CO-N((C;- Co)-alkyl);

and the physiologically tolerated salts thereof.

2. A compound of the formula I as claimed in claim 1, wherein the meanings are A 3-12 membered mono-, bi- or spirobicyclic ring which may comprise one or more heteroatoms from the group of N, O and S and the 3-12 membered ring may have further substituents such as F, Cl, Br, NO,, CF3;, OCF, CN, (C;-C¢)- alkyl, aryl, CON(R11)(R12), N(R13)(R14), OH, O-(C,-Cs)-alkyl, S-(C,-Cs¢)- alkyl, N(R15)CO(C,-Cg¢)-alkyl or COO-(C;-C¢)-alkyl; R11, R12, R13, R14, R15 independently of one another H, (C,-Cs)-alkyl, heterocycle; m 1; n 0,1; R1 R8, (C,-Ce)-alkylene-R8, (C,-Ce)-alkenylene-R9, (SO;)-R8, (SO,)-(C1-Ce)- alkylene-R8, (S0O,)-(C,-C¢)-alkenylene-R9, (C=0)-R8, (C=0)-(C;-Cs)- alkylene-R8, (C=0)NH-RS8, (C=0)-(C,-Cs)-alkenylene-R9, (C=0)-NH-(C,-C)- alkylene-R8, (C=0)-NH-(C,-C¢)-alkenylene-R9, COO-R8, COO-(C,;-Ce)- alkylene-R8, COO-(C,-C¢)-alkenylene-R9, alkynylene-R9, (C,-C;-alkyl)- heterocycle; RS, R9 independently of one another H, F, Cl, Br, I, OH, CFj3, aryl, heterocycle, (Cs- Cs)-cycloalkyl, where the rings or ring systems may be substituted up to 3 times by F, Cl, Br, I, OH, CF3, NO,, CN, OCF3, O-(C,;-C¢)-alkyl, (C;-C¢)-alkyl, NH,, CON(R11)(R12), N(R13)(R14), SO,-CH3, COOH, COO-(C,-Cg¢)-alkyl, CONH3; R2 H, F, Cl, Br, I, OH, CFs, CN, OCF;, O-(C,-C¢)-alkyl, O-(C,-C,)-alkoxy-(C;- Ca4)-alkyl, S-(C;-Ce)-alkyl, (C,-C¢)-alkyl, (C,-C¢)-alkenyl, (C3.Cs)-cycloalkyl, O-(C3-Cs)-cycloalkyl, (C;-Cg)-cycloalkenyl, O-(Cs-Cg)-cycloalkenyl, (C2-C)-

alkynyl, aryl, O-aryl, (C;-Cs)-alkylene-aryl, O-(C,-Cg)-alkylene-aryl, S-aryl, CON(R11)(R12), N(R13)(R14), (C,-C¢)-alkyl-N(R13)(R14), COOH, COO-(C:- Cs)-alkyl, COO-(C,-Cg)-alkenyl, CO-N((C,-C¢)-alkyl), heterocycle, where the heterocycle may not be bonded via a nitrogen atom; R3,R4,R5 independently of one another H, F, Cl, Br, I, OH, CF;, NO,, CN, OCF;, O-(Ci- Ce)-alkyl, O-(C;-C,)-alkoxy-(C;-Cy)-alkyl, S-(C;-Cg)-alkyl, (C,-C¢)-alkyl, (C>- C¢)-alkenyl, (C;-Cg)-cycloalkyl, O-(C3-Cg)-cycloalkyl, (C;-Cs)-cycloalkenyl, O- (C;-Csg)-cycloalkenyl, (C,-Ce)-alkynyl, aryl, O-aryl, (Co-Cg)-alkylene-aryl, O- (Cop-Cs)-alkylene-aryl, S-aryl, N((C;-Ce)-alkyl),, SO,-CH3;, COOH, COO-(C;- Ce)-alkyl, CO-N((C;-Ce)-alkyl)s; R6 H, F, Cl, Br, I, OH, CF;, NO,, CN, OCF;, O-(C;-C¢)-alkyl, O-(C;-Cs4)-alkoxy- (Cy-Cy)-alkyl, S-(C,-Ce)-alkyl, (C1-Ce)-alkyl, (C,-Cs)-alkenyl, (C3-Cs)- cycloalkyl, O-(C3-Cg)-cycloalkyl, (C3-Cg)-cycloalkenyl, O-(Cs-Cyg)- cycloalkenyl, (C,-Cg)-alkynyl, aryl, O-aryl, (C,-Cg)-alkylene-aryl, O-(C,-Csg)- alkylene-aryl, S-aryl, N((C,-Ce)-alkyl),, SO,-CH;, COOH, COO-(C;-Cs)-alkyl, CO-N((C1-Ce)-alkyl),; and the physiologically tolerated salts thereof.

3. A compound of the formula I as claimed in claim 1 or 2, wherein the meanings are A aryl, where the aryl ring may be substituted by F, Cl, Br, NO,, CF;, OCF;, CN, (C,-Ce)-alkyl, aryl, CON(R11)(R12), N(R13)(R14), OH, O-(C,-Cs)-alkyl, S-(C;-Ce)-alkyl, N(R15)CO(C;-Ce)-alkyl or COO-(C;-Ce)-alkyl; R11, R12, R13, R14, R15 independently of one another H, (C,-Cg)-alkyl; m 1; R1 (C,-Ce)-alkylene-R8, (C,-Ce)-alkenylene-R9;

R8, RY independently of one another H, F, Cl, Br, I, OH, CF, aryl, heterocycle, (Cs- Cs)-cycloalkyl, where the rings or ring systems may be substituted up to 3 times by F, Cl, Br, I, OH, CF3;, NO,, CN, OCF3, 0-(C,-Cg¢)-alkyl, (C,-Ce)-alkyl, NH,, CON(R11)(R12), N(R13)(R14), SO,-CH3, COOH, COO-(C,-Cq)-alkyl, CONH3; R2 H, F, Cl, Br, I, OH, CF;, CN, OCF3, O-(C;-Ce)-alkyl, (C,-Ce)-alkyl, COO-(C»- Ce)-alkenyl, N(R13)(R 14), (C-Ce)-alkyl-N(R13)(R14); R3 H; R4, RS independently of one another H, F, C], Br, OH, CF, OCF3, O-(C;-Ce)-alkyl, (Cy-Ce)-alkyl; R6 H; and the physiologically tolerated salts thereof.

4. A compound as claimed in one or more of claims 1 to 3, wherein the meanings are A aryl, where the aryl ring may be substituted by F, Cl, Br, NO,, CF3, OCF;, CN, (C1-Ce)-alkyl, aryl, CON(R11)(R12), N(R13)(R14), OH, 0O-(C,-Ce)-alkyl, S-(C,-Ce)-alkyl, N(R15)CO(C;-Cq)-alkyl or COO-(C,-Ce)-alkyl; R11, R12, R13, R14, R15 independently of one another H, (C,-Ce)-alkyl; m 1; n 0,1; R1 (C-Ce)-alkyl, (C,-Ce)-alkenyl; R2 H, OH, (C;-Ce)-alkyl, COO~(C2-Cs)-alkenyl, (C,-Ce)-alkyl-N(R13)(R14);

R3 H; R4 F, Cl, Br, OH, CF;, OCF3, O-(C,-Ce)-alkyl, (C,-Cs)-alkyl; RS H, F, Cl, Br, OH, CF;, OCF3, O-(C;-Cq)-alkyl, (C,-C¢)-alkyl; R6 H; and the physiologically tolerated salts thereof.

5. A compound as claimed in one or more of claims 1 to 4 for use as a medicament.

6. A medicament comprising one or more of the compounds as claimed in one or more of claims 1 to 4.

7. A medicament comprising one or more of the compounds as claimed in one or more of claims 1 to 4 and one or more anorectic active ingredients.

8. A medicament comprising one or more of the compounds as claimed in one or more of claims 1 to 4 and one or more statins.

9. A medicament as claimed in claim 6, wherein the other active ingredient comprises one or more antidiabetics, hypoglycemic active ingredients, HMGCoA reductase inhibitors, cholesterol absorption inhibitors, PPAR gamma agonists, PPAR alpha agonists, PPAR alpha/gamma agonists, fibrates, MTP inhibitors, bile acid absorption inhibitors, CETP inhibitors, polymeric bile acid adsorbents, LDL receptor inducers, ACAT inhibitors, antioxidants, lipoprotein lipase inhibitors, ATP-citrate lyase inhibitors, squalene synthetase inhibitors, lipoprotein(a) antagonists, lipase inhibitors, insulins, sulfonylureas, biguanides, meglitinides, thiazolidinediones, a-glucosidase inhibitors, active ingredients which act on the ATP-dependent potassium channel of the beta cells, CART agonists, NPY agonists, MC4 agonists, orexin agonists, H3 agonists, TNF agonists, CRF agonists, CRF BP antagonists, urocortin agonists, B3 agonists, MSH (melanocyte-stimulating hormone) agonists, CCK agonists, serotonin reuptake inhibitors, mixed sertoninergic and noradrenergic compounds, SHT agonists, bombesin agonists, galanin antagonists, growth hormones, growth hormone- a releasing compounds, TRH agonists, uncoupling protein 2 or 3 modulators, leptin agonists, DA agonists (bromocriptine, Doprexin), lipase/amylase inhibitors, PPAR modulators, RXR modulators or TR-B agonists or amphetamines.

10. A compound as claimed in one or more of claims 1 to 4 in combination with at least one other anorectic active ingredient for use as medicament for the prophylaxis or treatment of obesity.

11. A compound as claimed in one or more of claims 1 to 4 in combination with at least one other anorectic active ingredient for use as medicament for the prophylaxis or treatment of the type II diabetes.

12. A process for producing a medicament comprising one or more of the compounds as claimed in one or more of claims 1 to 4, which comprises mixing the active ingredient with a pharmaceutically suitable carrier and converting this mixture into a form suitable for administration.

13. The use of the compound as claimed in one or more of claims 1 to 4 for producing a medicament for weight reduction in mammals.

14. The use of the compound as claimed in one or more of claims 1 to 4 for producing a medicament for the prophylaxis or treatment of obesity.

15. The use of the compound as claimed in one or more of claims 1 to 4 for producing a medicament for the prophylaxis or treatment of type II diabetes.

16. The use of the compound as claimed in one or more of claims 1 to 4 for producing a medicament for the prophylaxis or treatment of metabolic syndrome.

17. The use of the compound as claimed in one or more of claims 1 to 4 for producing a medicament for the treatment of female and male sexual disorders. Co